GILD
Will this be a great VBIV buy in?I've been actively trading the recent VBIV bull run, and I still expect the bull run to continue from now until year's end. However, the stock is up over 100% in a very short time, and this may be the correction to this rapid movement.
I'm not actively trading this idea yet, but I will update the idea if I decide to short.
Remember folks, just ideas!
GILD - Nice Breakout !!Hello! Friends,
- We see a nice breakout on hourly chart.
- If NASDAQ:GILD breaks the support line at 77.38, so you can short it.
TQQQ Target:[$100.00] Target Date:[07/01/2020] ROI:[38%]NASDAQ-100 INDEX
The NASDAQ-100 Index includes 100 of the largest domestic and international non-financial companies listed on The NASDAQ Stock Market based on market capitalization. The Index reflects companies across major industry groups including computer hardware and software, telecommunications, retail/wholesale trade and biotechnology.
Last week, the Invesco QQQ Trust (QQQ) crossed the $100 billion in assets mark, joining three S&P 500-based ETFs and a total stock market offering from Vanguard.
CFRA rates QQQ as a five-star diversified U.S. equity fund, believing it has a high probability of outperforming in the next nine months due to its low costs and high reward potential, despite slightly elevated risks.
Exposure to the biotech sector which is poised to profit from therapeutics to treat the coronavirus and future pandemics.
Analyst Ratings
Firm Name____________Rating
FactSet ________________A
Ned Davis Research _____BUY
XTF Inc. ___________10 out of 10
Morningstar, Inc.* ___ 5 out of 5
Zacks Research ______Strong Buy
Top Holdings
MSFT
Microsoft Corp
11.92%
AAPL
Apple Inc
11.19%
INTC
Intel Corp
2.97%
CSCO
Cisco Systems Inc
2.11%
NVDA
Nvidia Corp
2.04%
ADBE
Adobe Inc
1.95%
PYPL
Paypal Holdings Inc
1.42%
AVGO
Broadcom Inc
1.19%
TXN
Texas Instruments Inc
1.18%
QCOM
Qualcomm Inc
0.98%
Gild Bullish trend-line PlayGilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Entry $77.50 area
Target $2 trailing stoploss
I been trading this stock for over a year now and once it form it's base, it usually hold itself very well in it's pattern.
we could've easily scalped this stock multiple time this month for easy gain if you just buy the dip at the trend line with a tight stoploss.
GILD: Initiated a longInitiated a long - possible 10% to 14% upside short term - looking at $88 maybe higher
GILD is getting net new committed business (orders) from outside the US market for Remdesivir
will feel much better once GILD clears the red zone - a retest into that zone won't be a very good sign.
Where is GILEAD going? Just trying to get a picture of GILEAD and where its heading.
Maybe it will be in Range here for a while ( near support line )
Maybe it should go down and touch MA 50 befor turning ?
Maybe we are goinf down to hard support at couse 65 ?
Maybe we just jump up from here ?
I am waiting to find a reversal pattern.
Yeah there are many ways to trade - what are you waiting for ?
SIMPLEINVEST
FACEBOOK
GILD - Bullish tunnel + triangle - buy at the bottomThe chart explains it all.
the market keeps raising against all odds in the middle of this world pandemic, ignoring all data and indicators... Why shorting then?
Buy the bottom of the tunnel sell at mid range before it gets to the danger zone and bounce back again
key points;
- price at the bottom of the tunnel
- price riding the EMA 50
- good buying risk reward
This will keep bouncing until it completes the triangle and break free
XBI Potential What is XBi?
XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund’s alternative take on the space earns it a place on our Opportunities List.
Looking like we could see a pull back here or breakout.
Risk and reward is in our favor here. if it rejects, it can go to $95 area, if it breaks out, we can just stoploss for $1.
SPX: Remdesivir hopes cannot save this economyGlobal debt out of control. How will all these companies who could barely manage their debt pre-Covid manage increased debt with higher borrowing costs and weakened consumer demand after Covid-19 lockdowns end?
Remdesivir was per Dr. Fauci "highly significant if you look at time to recovery." Sorry folks but it looks like GILD moved the goal posts (changed the endpoint) in the study and had to increase the patient enrollment substantially in order to achieve statistical significance. I'm a GILD shareholder, but this is not a Covid-19 magic bullet. I'm ecstatic if patients will be discharged earlier and if this helps to lessen the burden on our hospital systems, but based on comments to date, this treatment did not make a statistically significant impact on the death rate (Fauci seems to be hoping for a "trend")...in fact a separate study patients who go more drug died in a greater percentage (not statistically significant).
GDP contracting at faster rate than anticipated. Q2 will be a disaster. Q3 and Q4 will suffer too.
26 million and counting unemployed.
Germany now reporting a spike in infections (the European standard-bearer).
Singapore already had to go into lockdown after being touted as an Asian standard-bearer early in the crisis.
The FED doesn't have a clue what 2nd and 3rd order effects their market manipulation will have (and they've admitted as much)...hint: the future isn't pretty.
When SPX breaks the lower channel trend line and the RSI trend line, look out below.
GILD Analysis ||| it's a short term buy (2-5 months)The GILD price fold into the inside pitchork channel on the long term. This signal a long term downtrend, which does not serve visionary long term investment.
However, for the intermediate term analysis. GILD price follow channel patter as is in the second channel. Despite the extraordinary selling volume, the price found a strong support at 75$.
GILD next TP needs to be positioned at 89$.
If the price breaks the 89$ resistance with momentum, the next TP is at 103$.
Gilead in tested channelGILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.
Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel , meaning the Risk-Reward-Ratio is at a good stance.
A close below the 50sma would change the sentiment, and remove us from the channel.
GILEAD Short Term Uptrend Trade PlanTrade Plan for Gilead Sciences.
Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74).
Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance.
Upside for Gilead:
1a) Possible treatment for Covid-19 (Remdesivir)
1b) Possible 2nd wave of virus
2) Possible FDA approval of Arthritis drug
Downside for Gilead:
1) Leaked report of Remdesivir failing in China randomized trial, which was cancelled early due to low enrollment numbers. Bears clinging on hopes that the conclusion was inaccurate due to short duration of study
$GILD Holds Bullish Posture as Key Data Looms for Top TreatmentGILD is the leader on the treatment side of the game with its remdesivir asset. The market will likely react to every new development. But the chart is very constructive at this point.
However, everything will depend on new data from trials now underway around the world.
$IWM - How GILD may have saved the market (for now)Those who follow me know I have been bearish (and still am in the long term) since January. However looking at the IWM which has been a very good leading indicator of the market overall, the Gild news could have breathed a new lease of life to the market.
Looking at the actions a few days before the GILD news we can see that the IWM was rejected twice and closed below the resistance line.
In addition there was a bearish RSI divergence prior to the news. As a result, I think we could be headed higher now if we are able to break above the resistance line after bouncing off support. (If we are unable to break that resistance and fall below the current support then it could be game on for the shorts)
Also looking at the RSI in general, for now we are still following the trend line and still haven't gotten back to the 50% line, this may mean the rest of the market may be heading higher with minor pull backs.
With everything happening in the world one would expect that the stock market should be crashing but The Fed has been injecting so much liquidity into the market. We have to take the stock market one day at a time and deal with what it gives us.
Also there is too much negativity in the market right now and it shouldn't take much for the FED to get the market to move higher if and when it starts to buy ETFs since that could cause a short squeeze and take markets to higher highs.
Please do your DD before investing as this is just my opinion.
GILD Looking for a Long Entry After the Gap UpSUMMARY: Looking for a long entry on Gilead Sciences (GILD) after the gap up on news of a COVID treatment.
HEADLINE: Looking for a Long Entry After the Gap Up
TICKER: GILD
STRATEGY USED: Silver Scalper
Trend Confirmation = Range MA
Entry Signal = Bull/Bear Power
Exit Signal = Bull/Bear Power OR Range MA
---
DESCRIPTION:
1. With this strategy we enter long on Bull signals and exit on Bear signals when the trend is bullish.
2. The current trend on GILD is bullish according to our Alpha RMA (Green bar color).
3. We are currently looking for a Bull signal for a long entry.
4. We expect a stop and go off of S1 to get our long entry.
5. If we get the long entry at S1 we will be looking at R1 to see how the price reacts.
6. If S1 can't hold we will watching for a Bull signal in the S2 range.
---
NOTE: We conduct market analysis on a daily basis from a trend trading perspective using our own in house built tools. If you like any of the content we provide please leave a like and a follow to show your appreciation.
$GILD Gets Ready to Wag the DowGILD shares will open in the $90 area, it would appear (on Thursday evening). The hints on Remdesivir results for COVID-19 treatment suggest a significant response among severe patients.
Given that the world hangs in the balance, the stakes couldn't be higher. This stock will be the tail wagging the S&P for the next week.
Trade Journal: Long $GILD - 3/12/2020This is not my typical type of setup, however the prospects of GILD look very inciting. GILD is currently working on a coronavirus vaccine and is the closest to having a FDA approved vaccine in the future. Any positive announcements could cause GILD to spike in price as coronavirus fears continue. On the weekly chart, there is clear bottoming price action followed by accumulation recently due to the coronavirus news. The past few days, GILD has retraced back to it's breakout level due to the overall market weakness.
On the daily chart, GILD retraced to and rejected the high volume node in the 62-68 area.
Since this trade is outside of my usual timeframe, I am using 1/3rd risk on this trade.
Entry - 68.86
Stop loss - 61.90
Target - 80-90
This is considered a long term trade. I will exit depending on the trend on the daily chart rather than the 30m chart.
GILD support trendlineA trendline derives its authority from the number of times it has been touched or approached, the larger the number, the greater the significance.
